Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2200 participants.

Also called NCT02334969

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,200 participants (enrolled count) (from the registry)
Sponsor
Xiaofei Yu (from the registry)
Registry
  • NCT NCT02334969
Other papers using this trial's data
  • Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial Chinese journal of integrative medicine, 2022-12 DOI, PubMed 36251140

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02334969. Randomized; double masking; primary purpose prevention. Start 2016-04 (actual); primary completion 2018-08-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM
Intervention (Drug)
Naoxintong Capsule
Intervention (Drug)
Placebo
Lead sponsor
Xiaofei Yu (class: other)
Collaborator
Shanghai Municipal Science and Technology Commission (class: other government)

Record details

Record id
cardio:ct-nct02334969
Content hash
de7a906b120409eba8a66d7c2639164f0470acac34aca7e5a1247b977d098ee6